Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma

Authors

Susan Y Wu
Penny Q Fang
Ethan B Wang
Sairah Ahmed
Madeleine Duvic
Preetesh Jain
Luis E Malpica Castillo
Ranjit Nair
Raphael E Steiner
Paolo Strati
Auris O Huen
Swaminathan P Iyer
Chelsea C Pinnix
Bouthaina S Dabaja
Jillian R Gunther

Publication Date

1-1-2023

Journal

Advances in Radiation Oncology

Abstract

PURPOSE: Purpose: Radiation therapy (RT) and the antibody-drug conjugate brentuximab vedotin (BV) are standard-of-care treatment options for patients with certain B and T-cell lymphomas; however, there are limited data exploring the safety of concurrent BV and RT (BVRT).

METHODS AND MATERIALS: We performed a single institutional retrospective review of 44 patients who received BVRT.

RESULTS: Twenty percent of patients (9/44) developed new grade 2 or higher (G2+) hematologic toxicity (HT) after BVRT, which was associated with radiation dose (median dose of 35 Gy in those with new G2+ HT compared with 15 Gy in those without;

CONCLUSIONS: Our analysis demonstrates that the combination of BV and RT is well tolerated, though care should be taken during RT planning to reduce the risk of HT. This combination can be considered for patients in need of both local and systemic disease control.

Comments

PMID: 37448588